Published in J Am Chem Soc on February 05, 2003
Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol (2004) 3.18
Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol (2006) 2.68
Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther (2009) 2.08
Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther (2009) 1.55
The phosphoinositol-3-kinase-protein kinase B/Akt pathway is critical for Pseudomonas aeruginosa strain PAK internalization. Mol Biol Cell (2005) 1.49
Obligatory participation of macrophages in an angiopoietin 2-mediated cell death switch. Development (2007) 1.47
PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene (2008) 1.41
The role of Akt in the signaling pathway of the glycoprotein Ib-IX induced platelet activation. Blood (2007) 1.33
Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br J Pharmacol (2007) 1.33
Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factor-kappaB. Curr Neurovasc Res (2006) 1.22
Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells. Cancer Res (2008) 1.20
Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol Biol Cell (2008) 1.20
Remote postconditioning by humoral factors in effluent from ischemic preconditioned rat hearts is mediated via PI3K/Akt-dependent cell-survival signaling at reperfusion. Basic Res Cardiol (2010) 1.15
The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection. Int J Mol Med (2007) 1.13
A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. Br J Cancer (2010) 1.12
Lack of evidence for a role of TRB3/NIPK as an inhibitor of PKB-mediated insulin signalling in primary hepatocytes. Biochem J (2005) 1.09
Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells. Br J Cancer (2004) 1.09
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res (2005) 1.08
Aurora kinase A controls meiosis I progression in mouse oocytes. Cell Cycle (2008) 1.05
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem (2009) 1.04
The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. Prostate (2012) 1.01
Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells. PLoS One (2011) 1.01
p38alpha MAP kinase C-terminal domain binding pocket characterized by crystallographic and computational analyses. J Mol Biol (2009) 1.00
Interferon-gamma induces Fas trafficking and sensitization to apoptosis in vascular smooth muscle cells via a PI3K- and Akt-dependent mechanism. Am J Pathol (2006) 0.99
A PI3K pathway mediates hair cell survival and opposes gentamicin toxicity in neonatal rat organ of Corti. J Assoc Res Otolaryngol (2006) 0.99
Small-molecule inhibitors of the PI3K signaling network. Future Med Chem (2011) 0.98
Wnt1 neuroprotection translates into improved neurological function during oxidant stress and cerebral ischemia through AKT1 and mitochondrial apoptotic pathways. Oxid Med Cell Longev (2010) 0.98
Albumin endocytosis in proximal tubule cells is modulated by angiotensin II through an AT2 receptor-mediated protein kinase B activation. Proc Natl Acad Sci U S A (2005) 0.97
TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis (2005) 0.96
Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain. Curr Med Chem (2011) 0.93
c-Src-dependent EGF receptor transactivation contributes to ET-1-induced COX-2 expression in brain microvascular endothelial cells. J Neuroinflammation (2012) 0.92
Asymmetric PI(3,4,5)P3 and Akt signaling mediates chemotaxis of axonal growth cones. J Neurosci (2011) 0.92
Akt-dependent Pp2a activity is required for epidermal barrier formation during late embryonic development. Development (2009) 0.90
Insights into the structural specificity of the cytotoxicity of 3-deoxyphosphatidylinositols. J Am Chem Soc (2008) 0.90
Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells. Cell Death Differ (2012) 0.89
Phosphoinositide-dependent pathways in mouse sperm are regulated by egg ZP3 and drive the acrosome reaction. Dev Biol (2006) 0.88
Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape. Expert Opin Ther Pat (2011) 0.87
A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling. J Chem Inf Model (2011) 0.86
Identification of functional domains in AKT responsible for distinct roles of AKT isoforms in pressure-stimulated cancer cell adhesion. Exp Cell Res (2007) 0.86
ITK inhibitors in inflammation and immune-mediated disorders. Curr Top Med Chem (2009) 0.86
Regulation of intracellular pH by p90Rsk-dependent activation of an Na(+)/H(+) exchanger in starfish oocytes. J Biol Chem (2010) 0.85
Recent development of anticancer therapeutics targeting Akt. Recent Pat Anticancer Drug Discov (2011) 0.84
A prostacyclin analog prevents radiocontrast nephropathy via phosphorylation of cyclic AMP response element binding protein. Am J Pathol (2005) 0.83
Extreme Depletion of PIP3 Accompanies the Increased Life Span and Stress Tolerance of PI3K-null C. elegans Mutants. Front Genet (2013) 0.83
LIP expression is regulated by IGF-1R signaling and participates in suppression of anoikis. Mol Cancer (2011) 0.83
Understanding the stereospecific interactions of 3-deoxyphosphatidylinositol derivatives with the PTEN phosphatase domain. J Mol Graph Model (2010) 0.82
Characterization of AKT independent effects of the synthetic AKT inhibitors SH-5 and SH-6 using an integrated approach combining transcriptomic profiling and signaling pathway perturbations. BMC Cancer (2010) 0.81
Ceramide mediates nanovesicle shedding and cell death in response to phosphatidylinositol ether lipid analogs and perifosine. Cell Death Dis (2012) 0.81
Dexamethasone (DEX) induces Osmotic stress transcription factor 1 (Ostf1) through the Akt-GSK3β pathway in freshwater Japanese eel gill cell cultures. Biol Open (2013) 0.79
PDK1 inhibitors. Pharm Pat Anal (2012) 0.79
Functional Effects of WNT1-Inducible Signaling Pathway Protein-1 on Bronchial Smooth Muscle Cell Migration and Proliferation in OVA-Induced Airway Remodeling. Inflammation (2016) 0.79
Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells. Mol Cancer Ther (2011) 0.78
d-3-Deoxy-dioctanoylphosphatidylinositol induces cytotoxicity in human MCF-7 breast cancer cells via a mechanism that involves downregulation of the D-type cyclin-retinoblastoma pathway. Biochim Biophys Acta (2016) 0.75
Quebrachitol: Global Status and Basic Research. Nat Prod Bioprospect (2017) 0.75
Combined effect of protein kinase B inhibitor or extracellular signal-regulated kinase inhibitor against farnesyltransferase inhibition-induced apoptosis in SiHa cells. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer (2011) 4.37
Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest (2003) 4.06
Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila) (2010) 3.86
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat (2007) 3.78
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther (2002) 3.55
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene (2003) 3.32
Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat (2002) 2.95
Protein kinase cδ deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis Rheum (2013) 2.60
The phosphatase PHLPP controls the cellular levels of protein kinase C. J Biol Chem (2007) 2.24
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 2.22
Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal (2009) 2.11
The mRNA surveillance protein hSMG-1 functions in genotoxic stress response pathways in mammalian cells. Mol Cell (2004) 2.09
Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis (2005) 2.02
SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res (2008) 1.87
Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep (2009) 1.73
PTEN hamartoma tumor syndromes. Eur J Hum Genet (2008) 1.72
Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab (2013) 1.68
The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Mol Cell (2009) 1.64
Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol (2005) 1.64
A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem (2011) 1.58
Targeting Akt in cancer therapy. Anticancer Drugs (2007) 1.57
Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res (2007) 1.46
Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo. Cancer Res (2004) 1.45
Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res (2004) 1.43
Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res (2003) 1.38
Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res (2006) 1.38
Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J Exp Med (2003) 1.34
An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol (2005) 1.33
Characterization of ionic currents in human mesenchymal stem cells from bone marrow. Stem Cells (2005) 1.32
The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. Clin Cancer Res (2009) 1.27
Nicotine does not enhance tumorigenesis in mutant K-ras-driven mouse models of lung cancer. Cancer Prev Res (Phila) (2011) 1.27
Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes. Cancer Res (2005) 1.22
Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy. Autophagy (2007) 1.21
Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells. Cancer Res (2008) 1.20
Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16
Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death. Cancer Res (2005) 1.14
Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. Mol Cancer Ther (2006) 1.14
Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and -dependent mechanisms. J Biol Chem (2007) 1.14
A novel classification of lung cancer into molecular subtypes. PLoS One (2012) 1.13
Repositioning HIV protease inhibitors as cancer therapeutics. Curr Opin HIV AIDS (2008) 1.12
Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer. Proc Natl Acad Sci U S A (2013) 1.12
Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol Cancer Ther (2011) 1.09
Ion channels in mesenchymal stem cells from rat bone marrow. Stem Cells (2006) 1.09
Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. Cancer Prev Res (Phila) (2013) 1.08
Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet (2012) 1.04
Role of the small GTPase RhoA in the hypoxia-induced decrease of plasma membrane Na,K-ATPase in A549 cells. J Cell Sci (2007) 1.03
A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis. PLoS One (2009) 1.01
Na,K-ATPase alpha1-subunit dephosphorylation by protein phosphatase 2A is necessary for its recruitment to the plasma membrane. FASEB J (2006) 0.99
Design, synthesis, and evaluation of potent, nonpeptidic mimetics of second mitochondria-derived activator of caspases. J Med Chem (2009) 0.96
Importance of ligand reorganization free energy in protein-ligand binding-affinity prediction. J Am Chem Soc (2009) 0.96
Potent, orally bioavailable diazabicyclic small-molecule mimetics of second mitochondria-derived activator of caspases. J Med Chem (2008) 0.95
LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. J Clin Oncol (2009) 0.94
The nuclear protein expression levels of SNAI1 and ZEB1 are involved in the progression and lymph node metastasis of cervical cancer via the epithelial-mesenchymal transition pathway. Hum Pathol (2013) 0.94
The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers. Cancer Prev Res (Phila) (2009) 0.93
Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. Clin Cancer Res (2006) 0.93
Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer. Oncotarget (2014) 0.92
The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt. Expert Opin Investig Drugs (2004) 0.91
LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling. Cancer Res (2012) 0.91
Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases. Mol Cancer Ther (2011) 0.89
Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance. PLoS One (2011) 0.89
Ubiquitination participates in the lysosomal degradation of Na,K-ATPase in steady-state conditions. Am J Respir Cell Mol Biol (2009) 0.89
Strain-specific spontaneous and NNK-mediated tumorigenesis in Pten+/- mice. Neoplasia (2008) 0.88
Protein kinase A-Iα regulates Na,K-ATPase endocytosis in alveolar epithelial cells exposed to high CO(2) concentrations. Am J Respir Cell Mol Biol (2013) 0.87
Demonstration of calcium-activated transient outward chloride current and delayed rectifier potassium currents in Swine atrial myocytes. J Mol Cell Cardiol (2004) 0.87
A Cyp2a polymorphism predicts susceptibility to NNK-induced lung tumorigenesis in mice. Carcinogenesis (2011) 0.87
Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer (2006) 0.87
Induction of preneoplastic lung lesions in guinea pigs by cigarette smoke inhalation and their exacerbation by high dietary levels of vitamins C and E. Carcinogenesis (2004) 0.87
Myosin-Va restrains the trafficking of Na+/K+-ATPase-containing vesicles in alveolar epithelial cells. J Cell Sci (2009) 0.86
Effects of diltiazem and nifedipine on transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes. Br J Pharmacol (2005) 0.86
Nelfinavir inhibits maturation and export of herpes simplex virus 1. J Virol (2014) 0.86
Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of caspases. J Med Chem (2008) 0.86
A multishear microfluidic device for quantitative analysis of calcium dynamics in osteoblasts. Biochem Biophys Res Commun (2011) 0.85
Bivalent Smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents. J Med Chem (2011) 0.84
Lipid molecules induce p38α activation via a novel molecular switch. J Mol Biol (2012) 0.83
Identification of the amino acid region involved in the intercellular interaction between the β1 subunits of Na+/K+ -ATPase. J Cell Sci (2012) 0.83
A potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice. J Med Chem (2013) 0.81
Tobacco carcinogen-induced cellular transformation increases Akt activation in vitro and in vivo. Chest (2004) 0.81
Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics. J Mammary Gland Biol Neoplasia (2012) 0.81
Druggable drivers of lung cancer. Oncotarget (2013) 0.79
Modulating protein kinase C (PKC) to increase the efficacy of chemotherapy: stepping into darkness. Drug Resist Updat (2003) 0.79
PTEN hamartomatous tumor syndromes (PHTS): rare syndromes with great relevance to common cancers and targeted drug development. Crit Rev Oncol Hematol (2007) 0.79
Evaluation of a reliable and cost-effective method of DNA isolation for mouse genotyping. Biotechnol Lett (2012) 0.79
Impact of HIV on lung tumorigenesis in an animal model. AIDS (2015) 0.78
Outcome of international Federation of gynecology and obstetrics stage IIb cervical cancer from 2003 to 2012: an evaluation of treatments and prognosis: a retrospective study. Int J Gynecol Cancer (2015) 0.78
Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations. Clin Lung Cancer (2013) 0.78
Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells. Mol Cancer Ther (2011) 0.78
PPARgamma agonists follow an unknown TRAIL in lung cancer. Cancer Biol Ther (2007) 0.78
Management of reproductive health in Cowden syndrome complicated by endometrial polyps and breast cancer. Obstet Gynecol (2013) 0.77
Population pharmacokinetics and exposure-response of albinterferon alfa-2b. J Clin Pharmacol (2011) 0.77
Starting with the ABCs: Akt in breast cancer. Mol Cancer Ther (2011) 0.77
Disparities in cancer funding. Science (2004) 0.77
Targeting aberrant signal transduction pathways in lung cancer. Cancer Biol Ther (2004) 0.77
[Inhibitory effect of NaV1.9 gene silencing on proliferation, phagocytosis and migration in RAW264.7 cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (2013) 0.76
Gefitinib for refractory advanced non-small-cell lung cancer. Lancet (2006) 0.75